Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$305.53M
Close$
$-7.91
170.3% downside
Current Fair Value
170.3% downsideOvervalued by 170.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $305.53 Million |
|---|---|
| Enterprise Value | $457.22 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 1.01 |
| Outstanding Shares | 28,892,000 |
Return
| Return on Equity | -53.17% |
|---|---|
| Return on Assets | -19.70% |
| Return on Invested Capital | -19.63% |
Valuation & Multiples
| P/E Ratio | -6.13 |
|---|---|
| PEG | 14.54 |
| Price to Sales | 5.62 |
| Price to Book Ratio | 2.81 |
| Enterprise Value to Revenue | 6.61 |
| Enterprise Value to EBIT | -8.68 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | 1.6 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$17.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$17.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3812▲ 38.12% |
|---|---|
| Total Calls | 38,300▼ 67.43% |
| Total Puts | 14,600▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 125.22%▲ 33.43% |
|---|---|
| Total Invested | $338.10M▼ 18.74% |
| Investors Holding | 134▲ 2.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly